Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M <sup>pro</sup> and cathepsin LM. Sacco, Jun Wang, Chunlong Ma et al.|Science Advances|2020Cited by 400
Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter AssayChunlong Ma, Jun Wang, M. Sacco et al.|ACS Central Science|2021Cited by 200
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease InhibitorsNaoya Kitamura, Jun Wang, M. Sacco et al.|Journal of Medicinal Chemistry|2021Cited by 168
Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target SpecificityChunlong Ma, Jun Wang, Zilei Xia et al.|Journal of the American Chemical Society|2021Cited by 155
Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and BoceprevirZilei Xia, Jun Wang, M. Sacco et al.|ACS Pharmacology & Translational Science|2021Cited by 102